Market Cap 7.42M
Revenue (ttm) 0.00
Net Income (ttm) -19.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,800
Avg Vol 10,694
Day's Range N/A - N/A
Shares Out 668,000.00
Stochastic %K 66%
Beta 1.09
Analysts Hold
Price Target $12.50

Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 261 2900
Address:
70 Doppler, Irvine, United States
TopSarge
TopSarge Jun. 29 at 4:10 PM
$NVNO Watching how buyers respond
0 · Reply
YushimiCloud
YushimiCloud Jun. 24 at 7:02 PM
0 · Reply
envvenomedical
envvenomedical Jun. 24 at 12:55 PM
$NVNO Join us at 2:00 PM ET as we participate in the Webull Corporate Connect Virtual Webinar Series. Register Here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
1 · Reply
envvenomedical
envvenomedical Jun. 23 at 7:30 PM
$NVNO will be participating in the Webull Corporate Connect Virtual Webinar Series tomorrow, June 24th at 2:00 PM ET. Tune in here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
0 · Reply
envvenomedical
envvenomedical Jun. 22 at 1:39 PM
$NVNO to Present in the Webull Corporate Connect Webinar Series on Wednesday, June 24th at 2:00 PM ET Register here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D PR: https://envveno.com/envveno-medical-to-present-in-the-webull-corporate-connect-webinar-series/
1 · Reply
DegenStock
DegenStock Jun. 17 at 2:15 PM
$NVNO I’ve never seen a company have their own Stocktwits account to try to pump their own POS stock… if this isn’t a red flag, I don’t know what is. Probably Scumbag Berman behind the account. WORST CEO EVER, STEP DOWN. Everyone stay far away from this horrible company
1 · Reply
Icemanja
Icemanja Jun. 16 at 7:20 PM
$NVNO If this new product is so good insiders would switch to a shares compensation structure instead of cash payout to build trust and save money, after blowing up a 90mil MC. Hold your winners and cut your Losers.
0 · Reply
Icemanja
Icemanja Jun. 16 at 7:05 PM
$NVNO Had some time to waste and watched the segment. What a bunch of BS. Have they never heard of the placebo effect , they have zero provable proof the Venovalve worked apart from , what Berman said himself in the segment. " patient starts feeling better " . Yes they might have mitigated some of the issues Venovalve had with open surgery. But the concept of a standalone valve is still unproven , and they are basing this whole new trial on the same concept a Standalone valve to be the solution for CVI. They still think Venovalve is a success. How can you say a device is a success but can't prove it to the FDA. One question i have that Berman will never answer and JTC gets paid to smile and filter is. How did the results leak the day before the PR about failure, someone dumped 250k shares at market a day before the PR with 10k avg daily volume. Only very few retail buyers, institutional investors wont touch until they can get a deep discount. Even at this MC.
0 · Reply
envvenomedical
envvenomedical Jun. 4 at 6:44 PM
$NVNO 📅 Mark Your Calendar Join us on June 9th at 4 PM ET for a #VirtualInvestor Closing Bell segment featuring the latest company updates. Register here: https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration
1 · Reply
envvenomedical
envvenomedical Jun. 2 at 1:35 PM
$NVNO to Participate in the Virtual Investor Closing Bell Series on Tuesday, June 9that 4:00 PM ET Register here: https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration https://envveno.com/press-viewer/?i=166889
2 · Reply
Latest News on NVNO
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year

2026-05-07T20:35:58.000Z - 2 months ago

enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year


enVVeno Medical sees cash runway into 3Q27

2026-05-07T20:34:39.000Z - 2 months ago

enVVeno Medical sees cash runway into 3Q27


enVVeno Medical trading halted, news pending

2026-01-17T00:50:35.000Z - 6 months ago

enVVeno Medical trading halted, news pending


enVVeno Medical board approves 1-for-35 reverse stock split

2026-01-15T13:20:22.000Z - 6 months ago

enVVeno Medical board approves 1-for-35 reverse stock split


enVVeno Medical Announces Reverse Stock Split

Jan 15, 2026, 8:00 AM EST - 6 months ago

enVVeno Medical Announces Reverse Stock Split


enVVeno Medical trading resumes

2025-11-13T22:30:26.000Z - 8 months ago

enVVeno Medical trading resumes


enVVeno Medical receives unfavorable FDA decision for VenoValve

2025-11-13T22:05:19.000Z - 8 months ago

enVVeno Medical receives unfavorable FDA decision for VenoValve


enVVeno Medical trading halted, news pending

2025-11-13T21:55:16.000Z - 8 months ago

enVVeno Medical trading halted, news pending


enVVeno Medical reports Q3 EPS (23c) vs. (35c) last year

2025-10-31T12:15:43.000Z - 8 months ago

enVVeno Medical reports Q3 EPS (23c) vs. (35c) last year


enVVeno Medical Updates Regulatory Status of VenoValve(R)

Sep 15, 2025, 8:45 AM EDT - 10 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)


Why Is EnVVeno Medical Stock (NVNO) Down 70% Today?

2025-08-21T01:32:00.000Z - 11 months ago

Why Is EnVVeno Medical Stock (NVNO) Down 70% Today?


enVVeno Medical reports Q2 EPS (33c) vs. (31c) last year

2025-08-01T12:16:38.000Z - 1 year ago

enVVeno Medical reports Q2 EPS (33c) vs. (31c) last year


First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve


Hancock Jaffe Announces Executive Promotions

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions


TopSarge
TopSarge Jun. 29 at 4:10 PM
$NVNO Watching how buyers respond
0 · Reply
YushimiCloud
YushimiCloud Jun. 24 at 7:02 PM
0 · Reply
envvenomedical
envvenomedical Jun. 24 at 12:55 PM
$NVNO Join us at 2:00 PM ET as we participate in the Webull Corporate Connect Virtual Webinar Series. Register Here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
1 · Reply
envvenomedical
envvenomedical Jun. 23 at 7:30 PM
$NVNO will be participating in the Webull Corporate Connect Virtual Webinar Series tomorrow, June 24th at 2:00 PM ET. Tune in here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
0 · Reply
envvenomedical
envvenomedical Jun. 22 at 1:39 PM
$NVNO to Present in the Webull Corporate Connect Webinar Series on Wednesday, June 24th at 2:00 PM ET Register here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D PR: https://envveno.com/envveno-medical-to-present-in-the-webull-corporate-connect-webinar-series/
1 · Reply
DegenStock
DegenStock Jun. 17 at 2:15 PM
$NVNO I’ve never seen a company have their own Stocktwits account to try to pump their own POS stock… if this isn’t a red flag, I don’t know what is. Probably Scumbag Berman behind the account. WORST CEO EVER, STEP DOWN. Everyone stay far away from this horrible company
1 · Reply
Icemanja
Icemanja Jun. 16 at 7:20 PM
$NVNO If this new product is so good insiders would switch to a shares compensation structure instead of cash payout to build trust and save money, after blowing up a 90mil MC. Hold your winners and cut your Losers.
0 · Reply
Icemanja
Icemanja Jun. 16 at 7:05 PM
$NVNO Had some time to waste and watched the segment. What a bunch of BS. Have they never heard of the placebo effect , they have zero provable proof the Venovalve worked apart from , what Berman said himself in the segment. " patient starts feeling better " . Yes they might have mitigated some of the issues Venovalve had with open surgery. But the concept of a standalone valve is still unproven , and they are basing this whole new trial on the same concept a Standalone valve to be the solution for CVI. They still think Venovalve is a success. How can you say a device is a success but can't prove it to the FDA. One question i have that Berman will never answer and JTC gets paid to smile and filter is. How did the results leak the day before the PR about failure, someone dumped 250k shares at market a day before the PR with 10k avg daily volume. Only very few retail buyers, institutional investors wont touch until they can get a deep discount. Even at this MC.
0 · Reply
envvenomedical
envvenomedical Jun. 4 at 6:44 PM
$NVNO 📅 Mark Your Calendar Join us on June 9th at 4 PM ET for a #VirtualInvestor Closing Bell segment featuring the latest company updates. Register here: https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration
1 · Reply
envvenomedical
envvenomedical Jun. 2 at 1:35 PM
$NVNO to Participate in the Virtual Investor Closing Bell Series on Tuesday, June 9that 4:00 PM ET Register here: https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration https://envveno.com/press-viewer/?i=166889
2 · Reply
Icemanja
Icemanja May. 12 at 11:59 PM
$NVNO " Buy some put it away and see what we do !! " Alot of us did Berman!! And your incompetency and lies cost us millions. From the CEO who currently owns 6,350 shares , Chief Medical Officer -2,500 and the show stopper Chief Technology Officer 0 . But wait this is the only company you'll hear the CEO say is in a lock our period for the last 3 year. And that they will continue to execute. I think he mean execute another failure and total investor capital wipe out.
0 · Reply
VirtualInvestor
VirtualInvestor May. 12 at 2:11 PM
$NVNO joined a #WhatThisMeans segment to discuss the FDA’s first-ever IDE approval for a U.S. pivotal study evaluating a non-surgical replacement venous valve and what this could mean for the ~3 million U.S. patients suffering from DVI. https://vimeo.com/1191510104/dade9c74de?share=copy&fl=sv&fe=ci
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 1:04 PM
$NVNO Share Price: $9.88 Contract Selected: Aug 21, 2026 $2.5 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.13 – $0.16 Potential Upside: 63% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Vacuity
Vacuity May. 12 at 2:58 AM
$NVNO Berman trying to figure out how to squeeze every cent out of retail to line his pockets before this goes belly up
0 · Reply
cohunter9
cohunter9 May. 3 at 6:13 AM
$NVNO do not buy. You’ve been warned. Worse than trash. At least with trash, you can start a dumper fire.
0 · Reply
beaches911
beaches911 May. 1 at 10:19 PM
$NVNO I look forward to shorting this on every pop it gets
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 30 at 8:06 PM
$NVNO Trading at <$7M market cap vs $25M cash. Just got FDA approval to start their trial. PoC data from the 1st cohort should be available within cash runway.
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 30 at 7:58 PM
$NVNO The first stage of the TAVVE study, which is expected to commence later this year, will consist of 10 patients, whose 30-day safety results will be submitted to the FDA for review
0 · Reply
Icemanja
Icemanja Apr. 29 at 9:04 PM
$NVNO The reality is , not enough vested institutional investor interest here. If they do come it will only be via a offering at deep discount to current price because of the 50 mil ATM over hang. Berman got the ATM approved because he knew no institutional investor would touch NVNO until he get full product approval if that ever happens.
0 · Reply
Icemanja
Icemanja Apr. 29 at 2:10 PM
$NVNO And there you have it sell the news, ATM next
0 · Reply
DonVigo
DonVigo Apr. 29 at 1:48 PM
$NVNO Will end up like TTOO and Casava. Believe me!
0 · Reply
Bulut21
Bulut21 Apr. 29 at 1:16 PM
$NVNO enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve $SAGT $INHD $XTLB $AIXI
0 · Reply